Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-014197
Filing Date
2025-02-05
Accepted
2025-02-05 09:24:43
Documents
1
Period of Report
2025-02-03

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 7195
  Complete submission text file 0000950170-25-014197.txt   8632
Mailing Address 10835 ROAD TO THE CURE, SUITE 140 SAN DIEGO CA 92121
Business Address 10835 ROAD TO THE CURE, SUITE 140 SAN DIEGO CA 92121 (858) 465-6511
Erasca, Inc. (Issuer) CIK: 0001761918 (see all company filings)

EIN.: 831217027 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ERASCA, INC. 10835 ROAD TO THE CURE, SUITE 140 SAN DIEGO CA 92121
Business Address
Chacko David M. (Reporting) CIK: 0001871801 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40602 | Film No.: 25591123